Mellman I, Chen DS, Powles T, Turley SJ. The cancer-immunity cycle: indication, genotype, and immunotype. Immunity. 2023;56:2188–205. https://doi.org/10.1016/j.immuni.2023.09.011.

Article  PubMed  CAS  Google Scholar 

Rui R, Zhou L, He S. Cancer immunotherapies: advances and bottlenecks. Front Immunol. 2023;14:1212476. https://doi.org/10.3389/fimmu.2023.1212476.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Cortes J, Rugo HS, Cescon DW, Im SA, Yusof MM, Gallardo C, et al. Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer. N Engl J Med. 2022;387:217–26. https://doi.org/10.1056/NEJMoa2202809.

Article  PubMed  CAS  Google Scholar 

Schmid P, Cortes J, Dent R, McArthur H, Pusztai L, Kümmel S, et al. Overall survival with pembrolizumab in early-stage triple-negative breast cancer. N Engl J Med. 2024;391:1981–91. https://doi.org/10.1056/NEJMoa2409932.

Article  PubMed  CAS  Google Scholar 

Dushyanthen S, Beavis PA, Savas P, Teo ZL, Zhou C, Mansour M, et al. Relevance of tumor-infiltrating lymphocytes in breast cancer. BMC Med. 2015;13:202. https://doi.org/10.1186/s12916-015-0431-3.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Wu R, Oshi M, Asaoka M, Yan L, Benesch MGK, Khoury T, et al. Intratumoral tumor infiltrating lymphocytes (TILs) are associated with cell proliferation and better survival but not always with chemotherapy response in breast cancer. Ann Surg. 2023;278:587–97. https://doi.org/10.1097/SLA.0000000000005954.

Article  PubMed  PubMed Central  Google Scholar 

Nagahashi M, Ishikawa E, Nagai T, Kanaoka H, Oshiro A, Togashi Y, et al. Clinical utility of tumor-infiltrating lymphocyte evaluation by two different methods in breast cancer patients treated with neoadjuvant chemotherapy. Breast Cancer. 2025;32:404–15. https://doi.org/10.1007/s12282-025-01665-y.

Article  PubMed  PubMed Central  Google Scholar 

Hiam-Galvez KJ, Allen BM, Spitzer MH. Systemic immunity in cancer. Nat Rev Cancer. 2021;21:345–59. https://doi.org/10.1038/s41568-021-00347-z.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Araki K, Ito Y, Fukada I, Kobayashi K, Miyagawa Y, Imamura M, et al. Predictive impact of absolute lymphocyte counts for progression-free survival in human epidermal growth factor receptor 2-positive advanced breast cancer treated with pertuzumab and trastuzumab plus eribulin or nab-paclitaxel. BMC Cancer. 2018;18:982. https://doi.org/10.1186/s12885-018-4888-2.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Imamura M, Morimoto T, Egawa C, Fukui R, Bun A, Ozawa H, et al. Significance of baseline neutrophil-to-lymphocyte ratio for progression-free survival of patients with HER2-positive breast cancer treated with trastuzumab emtansine. Sci Rep. 2019;9:1811. https://doi.org/10.1038/s41598-018-37633-0.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Miyagawa Y, Yanai A, Yanagawa T, Inatome J, Egawa C, Nishimukai A, et al. Baseline neutrophil-to-lymphocyte ratio and C-reactive protein predict efficacy of treatment with bevacizumab plus paclitaxel for locally advanced or metastatic breast cancer. Oncotarget. 2020;11:86–98. https://doi.org/10.18632/oncotarget.27423.

Article  PubMed  PubMed Central  Google Scholar 

Miyoshi Y, Yoshimura Y, Saito K, Muramoto K, Sugawara M, Alexis K, et al. High absolute lymphocyte counts are associated with longer overall survival in patients with metastatic breast cancer treated with eribulin-but not with treatment of physician’s choice-in the EMBRACE study. Breast Cancer. 2020;27:706–15. https://doi.org/10.1007/s12282-020-01067-2.

Article  PubMed  PubMed Central  Google Scholar 

Sata A, Fukui R, Miyagawa Y, Bun A, Ozawa H, Fujimoto Y, et al. C-reactive protein and absolute lymphocyte count can predict overall survival of patients treated with eribulin. Anticancer Res. 2020;40:4147–56. https://doi.org/10.21873/anticanres.14414.

Article  PubMed  CAS  Google Scholar 

Natori K, Igeta M, Morimoto T, Nagahashi M, Akashi-Tanaka S, Daimon T, et al. Development and internal validation of a predictive model of overall and progression-free survival in eribulin-treated patients with breast cancer based on baseline peripheral blood parameters. Breast Cancer. 2025;32:500–11. https://doi.org/10.1007/s12282-025-01678-7.

Article  PubMed  PubMed Central  Google Scholar 

Togashi Y, Nagahashi M, Oshiro A, Sugimoto G, Mitsuyoshi A, Kanaoka H, et al. Clinical implications of peripheral blood biomarkers in patients with advanced breast cancer treated with trastuzumab emtansine and trastuzumab deruxtecan. Int J Clin Oncol. 2025;30:1331–40. https://doi.org/10.1007/s10147-025-02768-4.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12:31–46. https://doi.org/10.1158/2159-8290.CD-21-1059.

Article  PubMed  CAS  Google Scholar 

Yu J, Du W, Yan F, Wang Y, Li H, Cao S, et al. Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer. J Immunol. 2013;190:3783–97. https://doi.org/10.4049/jimmunol.1201449.

Article  PubMed  CAS  Google Scholar 

Adeegbe DO, Nishikawa H. Natural and induced T regulatory cells in cancer. Front Immunol. 2013;4:190. https://doi.org/10.3389/fimmu.2013.00190.

Article  PubMed  PubMed Central  Google Scholar 

Schlecker E, Stojanovic A, Eisen C, Quack C, Falk CS, Umansky V, et al. Tumor-infiltrating monocytic myeloid-derived suppressor cells mediate CCR5-dependent recruitment of regulatory T cells favoring tumor growth. J Immunol. 2012;189:5602–11. https://doi.org/10.4049/jimmunol.1201018.

Article  PubMed  CAS  Google Scholar 

Lindau D, Gielen P, Kroesen M, Wesseling P, Adema GJ. The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells. Immunology. 2013;138:105–15. https://doi.org/10.1111/imm.12036.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Li F, Zhao Y, Wei L, Li S, Liu J. Tumor-infiltrating Treg, MDSC, and IDO expression associated with outcomes of neoadjuvant chemotherapy of breast cancer. Cancer Biol Ther. 2018;19:695–705. https://doi.org/10.1080/15384047.2018.1450116.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Cho U, Park HS, Im SY, Yoo CY, Jung JH, Suh YJ, et al. Prognostic value of systemic inflammatory markers and development of a nomogram in breast cancer. PLoS ONE. 2018;13:e0200936. https://doi.org/10.1371/journal.pone.0200936.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Zhang M, Berndt BE, Chen JJ, Kao JY. Expression of a soluble TGF-beta receptor by tumor cells enhances dendritic cell/tumor fusion vaccine efficacy. J Immunol. 2008;181:3690–7. https://doi.org/10.4049/jimmunol.181.5.3690.

Article  PubMed  CAS  Google Scholar 

Zea AH, Rodriguez PC, Atkins MB, Hernandez C, Signoretti S, Zabaleta J, et al. Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res. 2005;65:3044–8. https://doi.org/10.1158/0008-5472.CAN-04-4505.

Article  PubMed  CAS  Google Scholar 

Kusmartsev S, Su Z, Heiser A, Dannull J, Eruslanov E, Kübler H, et al. Reversal of myeloid cell-mediated immunosuppression in patients with metastatic renal cell carcinoma. Clin Cancer Res. 2008;14:8270–8. https://doi.org/10.1158/1078-0432.CCR-08-0165.

Article  PubMed  CAS  Google Scholar 

Bailur JK, Gueckel B, Derhovanessian E, Pawelec G. Presence of Circulating Her2-reactive CD8 + T-cells is associated with lower frequencies of myeloid-derived suppressor cells and regulatory T cells, and better survival in older breast cancer patients. Breast Cancer Res. 2015;17:34. https://doi.org/10.1186/s13058-015-0541-z.

Article